Law360 (February 7, 2018, 6:40 PM EST) — The patent lawsuits filed by AbbVie Inc. and Besins Healthcare Inc. over generic testosterone replacement treatments were “anti-competitive weapons” used to delay competition for the brand-name drug AndroGel, an attorney for the Federal Trade …
